Oncolytics Biotech

August 02, 2019

Strike two for overheated South Korean biotech

Pexa-Vec fails earlier than expected, dealing exuberant South Korean biotech investors and the oncolytic virus field another blow.

October 24, 2018

Esmo 2018 – Adaptimmune gets the wooden spoon

The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.

September 21, 2018

Oncolytics prepares to tap US investors

The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.

September 13, 2018

Another must-have oncolytic virus asset for big pharma

February 21, 2018

Merck & Co makes biggest oncolytic virus bet since Amgen in 2011

December 13, 2016

Setbacks fail to stifle oncolytic virus business development

December 08, 2016

Ash winners and losers – Bluebird and Juno set the pulses racing

October 05, 2016

Interview – Boehringer beats a brave route with oncolytic virus deal

April 30, 2015

Adcom puts T-Vec on track to underwhelm

October 06, 2014

Acquisitions help define performance of mid and small cap stocks

September 22, 2014

Still unpartnered, but now worth a lot more

Load More